Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITRINE: Carboplatin in Early TNBC
NCT04296175Phase 3Active, not recruiting
- Sponsor
- Fudan University
- Start
- Mar 2020
- Primary completion
- Mar 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of carboplatin in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Mar 2020; status: active, not recruiting.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04296175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296175.